```
[Federal Register Volume 78, Number 106 (Monday, June 3, 2013)]
[Notices]
[Page 33097]
From the Federal Register Online via the Government Printing Office [http://www.gpo.gov/]
[FR Doc No: 2013-13043]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC-2013-0007; NIOSH-233]


NIOSH List of Antineoplastic and Other Hazardous Drugs in 
Healthcare Settings 2014: Proposed Additions and Deletions to the NIOSH 
Hazardous Drug List

AGENCY: National Institute for Occupational Safety and Health (NIOSH) 
of the Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of Draft Document Available for Public Comment.

-----------------------------------------------------------------------

SUMMARY: The National Institute for Occupational Safety and Health 
(NIOSH) of the Centers for Disease Control and Prevention (CDC) 
announces the availability of the following draft document for public 
comment entitled ``NIOSH List of Antineoplastic and Other Hazardous 
Drugs in Healthcare Settings 2014: Proposed Additions and Deletions to 
the NIOSH Hazardous Drug List.'' The document and instructions for 
submitting comments can be found at http://www.regulations.gov/.
    This guidance document does not have the force and effect of law.
    Public Comment Period: Comments must be received by August 2, 2013.

ADDRESSES: You may submit comments, identified by CDC-2013-0007 and 
Docket Number NIOSH-233, by either of the two following methods:
     Federal eRulemaking Portal: http://www.regulations.gov/. 
Follow the instructions for submitting comments.
     Mail: NIOSH Docket Office, Robert A. Taft Laboratories, 
MS-C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226.
    Instructions: All information received in response to this notice 
must include the agency name and the docket number (CDC-2003-0007; 
NIOSH-233). All relevant comments received will be posted without 
change to http://www.regulations.gov/, including any personal 
information provided. All electronic comments should be formatted as 
Microsoft Word. Please make reference to CDC-2013-0007 and Docket 
Number NIOSH-233.

SUPPLEMENTARY INFORMATION:
    Background: The NIOSH Alert: Preventing Occupational Exposures to 
Antineoplastic and Other Hazardous Drugs in Health Care Settings was 
published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). 
This Alert contained Appendix A which was a list of drugs that were 
deemed to be hazardous and may require special handling. This list of 
hazardous drugs was updated in 2010 and 2012 and covered all new 
approved drugs and drugs with new warning up to December 2009. (http://www.cdc.gov/niosh/docs/2010-167/; http://www.cdc.gov/niosh/docs/2012-150/). Between January 2010 and December 2011, 48 new drugs received 
FDA approval and 276 drugs received special warnings (usually black box 
warnings) based on reported adverse effects in patients. From this list 
of 324 drugs, 42 drugs were identified by NIOSH as candidate hazardous 
drugs. Four of these drugs had safe handling recommendations from the 
manufacturer and NIOSH is following the recommendations of the 
manufacturers. Therefore, these four drugs will be listed as hazardous 
without requiring further review. A panel consisting of peer reviewers 
and stakeholders was asked to review and comment on the remaining 38 
potentially hazardous drugs. In addition, the panel members were asked 
to comment on the addition of one drug requested by several 
stakeholders and the removal of one drug from the 2012 Hazardous Drug 
List. Reviewers were not asked to provide a consensus opinion and NIOSH 
made the final determination regarding additions and deletions to the 
2014 hazardous drug list.
    NIOSH reviewed the recommendations of the peer reviewers and 
stakeholders and determined that 24 drugs in addition to the 4 drugs 
with manufacturer's warnings, were determined to have one or more 
characteristics of a hazardous drug and this list of 28 drugs is being 
published for comment in CDC-2013-0007 and NIOSH Docket Number 233. In 
addition, 1 drug from the 2012 Hazardous Drug List is being considered 
for removal. The complete list of these drugs can be found at: http://www.regulations.gov/ as a supporting document.

FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A. 
Taft Laboratories, 4676 Columbia Parkway, MS-C26, Cincinnati, Ohio 
45226, telephone (513) 533-8132, Email hazardousdrugs@cdc.gov.

     Dated: May 24, 2013.
John Howard,
Director, National Institute for Occupational Safety and Health, 
Centers for Disease Control and Prevention.
[FR Doc. 2013-13043 Filed 5-31-13; 8:45 am]
BILLING CODE 4163-19-P
```